This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JCAR023

Juno Therapeutics Inc.

Drug Names(s): Engineered Neuroblastoma Cellular Immunotherapy-01, Chimeric Antigen Receptor T Cells, CD171 CAR T, L1CAM, ENCIT-01

Description: ENCIT-01 (Engineered Neuroblastoma Cellular Immunotherapy) is a chimeric antigen receptor (CAR) T cell product comprised of autologous T cells. After aphresis, the patient's T cells are lentivirally transduced to express a CD171 CAR and a truncated EGFR receptor.


JCAR023 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug